Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia
The DOI matches its Crossref record; 65 of the 67 references it cites were found in a registry or an index.
Abstract
Evidence that the metabolism of phospholipids and polyunsaturated fatty acids (PUFA) is abnormal in schizophrenia provided the rationale for intervention studies using PUFA supplementation. An initial open label study indicating efficacy for n-3 PUFA in schizophrenia led to two small double-blind pilot studies. The first study was designed to distinguish between the possible effects of two different n-3 PUFA: eicosapentaenoic acid (EPA) and docohexaenoic acid (DHA). Forty-five schizophrenic patients on stable antipsychotic medication who were still symptomatic were treated with either EPA, DHA or placebo for 3 months. Improvement on EPA measured by the Positive and Negative Syndrome Scale (PANSS) was statistically superior to both DHA and placebo using changes in percentage scores on the total PANSS. EPA was significantly superior to DHA for positive symptoms using ANOVA for repeated measures. In the second placebo-controlled study, EPA was used as a sole treatment, though the use of antipsychotic drugs was still permitted if this was clinically imperative. By the end of the study, all 12 patients on placebo, but only eight out of 14 patients on EPA, were taking antipsychotic drugs. Despite this, patients taking EPA had significantly lower scores on the PANSS rating scale by the end of the study. It is concluded that EPA may represent a new treatment approach to schizophrenia, and this requires investigation by large-scale placebo-controlled trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, when Ω3FA is given as add-on therapy, double-blind, placebo-controlled trials have found an added therapeutic benefit, demonstrated by improvements in the Positive and Negative Syndrome Scale (PANSS) [83,85,86].”
From Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health (2022) · cites this paper as [86]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Prediction of psychosis. A step towards indicated prevention of schizophrenia.
Yung, A. R., Phillips, L., McGorry, P. D., McFarlane, C. A., Francey, S. M., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998) · PubMed · Cited by 698
Prediction of psychosis: A step towards indicated prevention of schizophrenia
Yung, A. R., Phillips, L. J., McGorry, P. D., McFarlane, C. A., Francey, S., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297602 · Cited by 630
Pettegrew, J. W. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810300075011 · Cited by 481
De Caterina, R., Cybulsky, M. I., Clinton, S. K., Gimbrone, M. A., & Libby, P. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.11.1829 · Cited by 470
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Horrobin, D. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00151-5 · Cited by 455
Delion, S., Chalon, S., Guilloteau, D., Besnard, J., & Durand, G. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66041582.x · Cited by 336
A role for phospholipid polyunsaturation in modulating membrane protein function
Litman, B. J., & Mitchell, D. C. (1996) · Lipids · doi:10.1007/bf02637075 · Cited by 282
A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases
Glen, A. I. M., Glen, E. M. T., Horrobin, D. F., Vaddadi, K. S., Spellman, M., Morse-Fisher, N., Ellis, K., & Skinner, F. S. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90084-1 · Cited by 251
Research works printed but not linked: 2
- Mellor, 1996, Omega-3 fatty acid supplementation in schizophrenic patients, Human Psychopharmacol., 11, 39, 10.1002/(sici)1099-1077(199601)11:1<39::aid-hup742>3.0.co;2-# · doi:10.1002/(sici)1099-1077(199601)11:1<39::aid-hup742>3.0.co;2-#
- Shah, 2000, Lack of niacin skin flush response in unmedicated schizophrenic patients, Schizophr. Res
Cited by
Recovery of microalgal biomass and metabolites: Process options and economics
Molina Grima, E., Belarbi, E.-H., Acién Fernández, F. G., Robles Medina, A., & Chisti, Y. (2003) · Biotechnology Advances · doi:10.1016/s0734-9750(02)00050-2 · Cited by 2,286
Functional Roles of Fatty Acids and Their Effects on Human Health
Calder, P. C. (2015) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607115595980 · Cited by 1,160
Djuricic, I., & Calder, P. C. (2021) · Nutrients · doi:10.3390/nu13072421 · Cited by 1,015
“The first trial of omega-3 PUFAs in schizophrenia 405 identified clinical improvement with EPA (2 g/day), but not with DHA [113], while sub- 406 sequent trials also showed benefit with EPA [114,115], but not all studies have seen this 407 [116].”
BackgroundBrenna, J. T., Salem, N., Sinclair, A. J., & Cunnane, S. C. (2009) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.01.004 · Cited by 863
Atypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Metadata
- Authors
- Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K.
- Affiliations
- Northern General Hospital (GB)
- Sir Sayajirao General Hospital Medical College (IN)
- Corresponding author
- Peet, Malcolm
- ORCID
- Vankar, G.K.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 49
- Issue
- 3
- Pages
- 243-251
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W1975464025
- Cited by
- 329
- References
- 67
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 10 · 2018: 6 · 2017: 14 · 2016: 11 · 2015: 19 · 2014: 15 · 2013: 14 · 2012: 14
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- eicosapentaenoic acid, docosahexaenoic acid
- MeSH terms
- Adult, Arachidonic Acids, Docosahexaenoic Acids, Double-Blind Method, Humans, Pilot Projects, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. https://app.cochat.ai/papers/10.1016/s0920-9964(00)00083-9
- The paper
- Peet, M., Brind, J., Ramchand, C. N., Shah, S., & Vankar, G. K. (2001). Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research. https://doi.org/10.1016/s0920-9964(00)00083-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.